標題: Titlebook: Cardiovascular Safety in Drug Development and Therapeutic Use; New Methodologies an J. Rick Turner,Dilip R. Karnad,Snehal Kothari Book 2017 [打印本頁] 作者: Inoculare 時間: 2025-3-21 18:22
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use影響因子(影響力)
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use影響因子(影響力)學科排名
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use網(wǎng)絡(luò)公開度
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use網(wǎng)絡(luò)公開度學科排名
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use被引頻次
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use被引頻次學科排名
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use年度引用
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use年度引用學科排名
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use讀者反饋
書目名稱Cardiovascular Safety in Drug Development and Therapeutic Use讀者反饋學科排名
作者: 尖牙 時間: 2025-3-21 20:14 作者: Water-Brash 時間: 2025-3-22 02:16 作者: 加強防衛(wèi) 時間: 2025-3-22 05:51
J. Rick Turner,Dilip R. Karnad,Snehal KothariCutting-edge descriptions and explanations of state-of-the-art cardiovascular safety assessments enable readers to get up to speed quickly. No other book provides such a comprehensive overview of one 作者: 使害羞 時間: 2025-3-22 12:22
http://image.papertrans.cn/c/image/221984.jpg作者: MIRE 時間: 2025-3-22 13:42 作者: MIRE 時間: 2025-3-22 17:24
978-3-319-82085-9Springer International Publishing Switzerland 2017作者: 仲裁者 時間: 2025-3-22 22:21 作者: 永久 時間: 2025-3-23 05:02
https://doi.org/10.1007/BFb0093144onsequently changing a patient’s biology for the better. Unfortunately, drugs can also lead to undesirable biological consequences, including adverse cardiovascular events. Before discussing the nature of these undesirable consequences and the methodologies for their prospective exclusion in subsequ作者: Osmosis 時間: 2025-3-23 06:33 作者: 盲信者 時間: 2025-3-23 11:52 作者: URN 時間: 2025-3-23 14:26
Demonstration of a matrix Laboratory, the focus moves to assessments of safety. As will be seen in the first part of this chapter, general safety assessments are conducted quite differently from those for efficacy, in that descriptive statistics are used as opposed to hypothesis testing. However, in the domain of cardiovascular safety,作者: 著名 時間: 2025-3-23 19:09 作者: BLOT 時間: 2025-3-24 02:07 作者: acrimony 時間: 2025-3-24 02:25 作者: 文件夾 時間: 2025-3-24 09:45 作者: DIKE 時間: 2025-3-24 13:55
https://doi.org/10.1007/BFb0075155ne-Gill et al. 2014; Kennelly and Esaian 2013), our attention falls on increases. As was noted in Sect. ., high blood pressure is authoritative regarded as the greatest threat to the global burden of disease (Horton 2013; Das and Samarasekera 2013; Lim et al. 2013). As hypertension has been studied 作者: 艱苦地移動 時間: 2025-3-24 17:07 作者: 調(diào)整校對 時間: 2025-3-24 21:15 作者: 整潔 時間: 2025-3-25 00:59
Cardiovascular Structure, Function, and Pathophysiology each case, attention falls first on the heart, since multiple subsequent chapters focus on proarrhythmia. Nonetheless, discussions of the cardiovascular system are also pertinent to topics addressed later in the book.作者: 我悲傷 時間: 2025-3-25 07:16
https://doi.org/10.1007/978-0-8176-8259-0duced via the large-scale cultivation of microbial or mammalian cells, which are much larger. For example, the immunoglobulin G (IgG) antibody is around 25,000 atoms and has a molecular weight of approximately 150 kilodaltons (Azbio web site).作者: 巨頭 時間: 2025-3-25 07:34 作者: infarct 時間: 2025-3-25 13:55 作者: 碎石頭 時間: 2025-3-25 17:50
Robert E Barnhill,James H Brownvious chapters. As we move into discussions related to the therapeutic use of drugs that have received marketing approval, the observation by Garattini (2010) that “drug authorization, prescription, and utilization are all based on benefit-risk assessment” provides an integrated perspective on this topic.作者: Pedagogy 時間: 2025-3-25 22:20 作者: Brittle 時間: 2025-3-26 00:27 作者: 使習慣于 時間: 2025-3-26 08:01 作者: 郊外 時間: 2025-3-26 11:10
The Proarrhythmic Cardiac Safety Regulatory Landscape Circa 2005–2015: Drug-Induced hERG Channel Blo be prescribed the drug should it subsequently be approved for marketing. The second step is to remain alert to unexpected cardiac adverse drug reactions during its therapeutic use. This chapter’s focus is the first step.作者: STALL 時間: 2025-3-26 13:05
The Central Role of Cardiovascular Safety in Drug Development and Therapeutic Useduced via the large-scale cultivation of microbial or mammalian cells, which are much larger. For example, the immunoglobulin G (IgG) antibody is around 25,000 atoms and has a molecular weight of approximately 150 kilodaltons (Azbio web site).作者: Lamina 時間: 2025-3-26 17:12 作者: Forehead-Lift 時間: 2025-3-26 22:49
Analyzing and Reporting Safety Data hypothesis-testing approaches are employed to investigate the potential occurrence of specific cardiac and cardiovascular adverse events. In the language introduced in this chapter, these can be regarded as adverse events of special interest.作者: 預定 時間: 2025-3-27 04:11 作者: 討厭 時間: 2025-3-27 05:42 作者: NEEDY 時間: 2025-3-27 12:00 作者: 平靜生活 時間: 2025-3-27 13:42
Multiexponential Fitting Methods,&A R3’s release, which we collectively refer to as the Early QTc Assessment Initiative, are described in this chapter by discussing several publications that preceded its release: ICH E14 Q&A R3 itself is then addressed in Sect. 8.7.作者: 河潭 時間: 2025-3-27 17:49 作者: Enteropathic 時間: 2025-3-28 00:44 作者: 陰郁 時間: 2025-3-28 02:51 作者: 切碎 時間: 2025-3-28 10:14 作者: engagement 時間: 2025-3-28 14:11
Book 2017ions of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future.? Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive .in vitro?.Proarrhythmia Ass作者: 花束 時間: 2025-3-28 17:39
The Central Role of Cardiovascular Safety in Drug Development and Therapeutic Usethat are used to treat or prevent biological states of clinical concern. The term pharmaceutical drug typically refers to a small-molecule drug (around 20–100 atoms, with a molecular weight of less than 900 daltons), while the term biopharmaceutical drug refers to macromolecules, often a protein pro作者: 最初 時間: 2025-3-28 19:51
Drug Structures and the Biological Basis of Drug Responsesonsequently changing a patient’s biology for the better. Unfortunately, drugs can also lead to undesirable biological consequences, including adverse cardiovascular events. Before discussing the nature of these undesirable consequences and the methodologies for their prospective exclusion in subsequ作者: Neutropenia 時間: 2025-3-28 23:16 作者: 樹上結(jié)蜜糖 時間: 2025-3-29 06:37
Analyzing and Reporting Efficacy Data shining armor” that rides to our assistance and facilitates the collection, analysis, and interpretation of optimal-quality data as the basis for rational decision-making at all stages of the process (Durham and Turner 2008). In this and the following two chapters, we have resisted the temptation t作者: Sputum 時間: 2025-3-29 08:56
Analyzing and Reporting Safety Data the focus moves to assessments of safety. As will be seen in the first part of this chapter, general safety assessments are conducted quite differently from those for efficacy, in that descriptive statistics are used as opposed to hypothesis testing. However, in the domain of cardiovascular safety,作者: venous-leak 時間: 2025-3-29 12:39
The Proarrhythmic Cardiac Safety Regulatory Landscape Circa 2005–2015: Drug-Induced hERG Channel Blol development whether a noncardiac drug has the propensity to lead to the polymorphic ventricular dysrhythmia . (Dessertenne 1966) in patients who may be prescribed the drug should it subsequently be approved for marketing. The second step is to remain alert to unexpected cardiac adverse drug reacti作者: CRACY 時間: 2025-3-29 16:30 作者: indecipherable 時間: 2025-3-29 23:05
The Comprehensive In Vitro Proarrhythmia Assay Initiativetions of the nonclinical proarrhythmic cardiac safety regulatory landscape. Underlying this initiative is the fact that drug-induced .. reduction and QTc interval prolongation are far from ideal surrogates for actual proarrhythmic risk, the true concern in the domain of proarrhythmic cardiac safety.作者: 寬敞 時間: 2025-3-30 01:36 作者: PLE 時間: 2025-3-30 07:16
